Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY10 | O00398 | 12/20 | 0.72 |
| ▸ | GPR174 | Q9BXC1 | 9/20 | 0.72 |
| ▸ | GPR34 | Q9UPC5 | 6/20 | 0.72 |
| ▸ | LPAR1 | Q92633 | 6/20 | 0.70 |
| ▸ | LPAR4 | Q99677 | 3/20 | 0.70 |
| ▸ | LPAR5 | Q9H1C0 | 3/20 | 0.70 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.70 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.70 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.70 |
| ▸ | LPAR6 | P43657 | 2/20 | 0.70 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.64 |
| ▸ | CES2 | O00748 | 1/20 | 0.61 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31442365 | 1.00 | P2RY10 (0.72) | P2RY10GPR174GPR34LPAR1LPAR4 | |
| SCHEMBL31442370 | 1.00 | P2RY10 (0.72) | P2RY10GPR174GPR34LPAR1LPAR4 | |
| SCHEMBL274812 | 1.00 | P2RY10 (0.72) | P2RY10GPR174GPR34LPAR1LPAR4 | |
| SCHEMBL31442542 | 1.00 | P2RY10 (0.72) | P2RY10GPR174GPR34LPAR1LPAR4 | |
| SCHEMBL21464913 | 1.00 | P2RY10 (0.72) | P2RY10GPR174GPR34LPAR1LPAR4 | |
| SCHEMBL14924219 | 1.00 | P2RY10 (0.72) | P2RY10GPR174GPR34LPAR1LPAR4 | |
| SCHEMBL15386593 | 1.00 | P2RY10 (0.72) | P2RY10GPR174GPR34LPAR1LPAR4 | |
| SCHEMBL14882712 | 1.00 | P2RY10 (0.72) | P2RY10GPR174GPR34LPAR1LPAR4 | |
| SCHEMBL13854646 | 1.00 | P2RY10 (0.72) | P2RY10GPR174GPR34LPAR1LPAR4 | |
| SCHEMBL31442348 | 1.00 | P2RY10 (0.72) | P2RY10GPR174GPR34LPAR1LPAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4607189-A2 | UNIVERSAL LIPID QUANTITATIVE STANDARDS FOR USE IN LIPIDOMICS | Avanti Polar Lipids, LLC (US) | 2025-08-27 | — | — | EP | disclosed |
| US-12247981-B2 | Method of diagnosing cancer based on lipidomic analysis of a body fluid | FONS JK GROUP, A.S. (CZ) | 2025-03-11 | — | — | US | disclosed |
| US-11872313-B2 | Prodrug compositions, prodrug nanoparticles, and methods of use thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-01-16 | — | — | US | disclosed |
| US-20220334136-A1 | UNIVERSAL LIPID QUANTITATIVE STANDARDS FOR USE IN LIPIDOMICS | AVANTI POLAR LIPIDS, LLC (US) | 2022-10-20 | — | — | US | disclosed |
| EP-3980788-A2 | UNIVERSAL LIPID QUANTITATIVE STANDARDS FOR USE IN LIPIDOMICS | Avanti Polar Lipids, LLC (US) | 2022-04-13 | — | — | EP | disclosed |
| CN-114144679-A | Universal lipid quantitation standard for use in lipidomics | 阿凡提极性脂质有限责任公司 | 2022-03-04 | — | — | CN | disclosed |
| US-9498439-B2 | Prodrug compositions, prodrug nanoparticles, and methods of use thereof | WASHINGTON UNIVERSITY (US) | 2016-11-22 | — | — | US | disclosed |
| US-20160279060-A1 | PRODRUG COMPOSITIONS, PRODRUG NANOPARTICLES, AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-09-29 | — | — | US | disclosed |
| US-20130122100-A1 | PRODRUG COMPOSITIONS, PRODRUG NANOPARTICLES, AND METHODS OF USE THEREOF | THE WASHINGTON UNIVERSITY (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160279060-A1 | PRODRUG COMPOSITIONS, PRODRUG NANOPARTICLES, AND METHODS OF USE THEREOF | FAP, PNP, TYMP | P2RY10 1106/4885GPR174 1515/4885GPR34 3173/4885 |
| US-20130122100-A1 | PRODRUG COMPOSITIONS, PRODRUG NANOPARTICLES, AND METHODS OF USE THEREOF | PHOSPHO1, PTDSS1, SMPD3 | P2RY10 916/4885GPR174 1841/4885GPR34 3017/4885 |
| US-11872313-B2 | Prodrug compositions, prodrug nanoparticles, and methods of use thereof | FAP, PNP, TYMP | P2RY10 1106/4885GPR174 1515/4885GPR34 3173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.